SCHEMBL3309747

SCHEMBL3309747

O=C1CCc2cc(-c3ccc(Cl)cc3)cnc2N1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.56
AURKA O14965 1/20 0.56
DAPK3 O43293 1/20 0.56
PRKD3 O94806 1/20 0.56
MAP4K4 O95819 1/20 0.56
ABL1 P00519 1/20 0.56
NTRK1 P04629 1/20 0.56
CSF1R P07333 1/20 0.56
RET P07949 1/20 0.56
MET P08581 1/20 0.56
PDGFRB P09619 1/20 0.56
PIM1 P11309 1/20 0.56
FGFR1 P11362 1/20 0.56
PDGFRA P16234 1/20 0.56
FLT1 P17948 1/20 0.56
LTK P29376 1/20 0.56
GRK5 P34947 1/20 0.56
KDR P35968 1/20 0.56
MAP2K2 P36507 1/20 0.56
FLT3 P36888 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1258081 0.85 ABL1 (0.56) CHEK1AURKADAPK3PRKD3MAP4K4
SCHEMBL4891646 0.83 KIF11 (0.62) CHEK1AURKADAPK3PRKD3MAP4K4
SCHEMBL8388712 0.77 ASIC3 (0.62) CHEK1AURKADAPK3PRKD3MAP4K4
SCHEMBL3307966 0.75 KIF11 (0.68) NTRK1METFGFR1KDRMAP2K2
SCHEMBL19430357 0.75 ABL1 (0.45) CHEK1AURKADAPK3PRKD3MAP4K4
SCHEMBL17081150 0.74 MB (0.58) CHEK1AURKADAPK3PRKD3MAP4K4
SCHEMBL1396298 0.72 ABL1 (0.67) CHEK1AURKADAPK3PRKD3MAP4K4
SCHEMBL31116823 0.72 CYP1A2 (0.44) CHEK1AURKADAPK3PRKD3MAP4K4
SCHEMBL5873863 0.72 KDR (1.00) CHEK1AURKADAPK3PRKD3MAP4K4
SCHEMBL730152 0.72 PIK3CA (0.55) CHEK1AURKADAPK3PRKD3MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952007-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2015-02-10 US disclosed
US-8664379-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2014-03-04 US disclosed
US-20130096122-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. (US) 2013-04-18 US disclosed
US-20100113514-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113514-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, KCNH2, KCNH3 CHEK1 4456/4885AURKA 2921/4885DAPK3 905/4885
US-20130096122-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, KCNH2, CACNA1E CHEK1 4431/4885AURKA 2994/4885DAPK3 991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.